Mitral valve repair is better than mitral valve replacement in native mitral valve endocarditis: Results from a prospective matched cohort.


Journal

Archives of cardiovascular diseases
ISSN: 1875-2128
Titre abrégé: Arch Cardiovasc Dis
Pays: Netherlands
ID NLM: 101465655

Informations de publication

Date de publication:
Mar 2022
Historique:
received: 17 08 2021
revised: 05 02 2022
accepted: 07 02 2022
pubmed: 8 3 2022
medline: 6 5 2022
entrez: 7 3 2022
Statut: ppublish

Résumé

In native mitral valve infective endocarditis (NMIE), the respective values of mitral valve repair (MVRep) and replacement (MVR) are still debated. To compare MVRep and MVR in a large prospective matched cohort. Between 2010 and 2017, all consecutive patients operated on for NMIE in our centre were included prospectively. Clinical and outcome features were compared between the two groups. Primary endpoint was event-free survival, including death, reoperation and relapse. Univariate and multivariable survival analyses and a propensity score analysis were performed. Among 152 patients, 115 (75.7%) underwent MVRep, and 37 (24.3%) MVR. Median follow-up was 28±22months. Surgery was performed during the active phase in 75.0% of patients (25.7% on an urgent basis). Compared with the MVRep group, patients in the MVR group were more frequently intravenous drug abusers (10.8% vs. 0.9%; P=0.016), had a more frequent history of rheumatic fever (13.5% vs. 0%; P=0.001), more aortic abscesses (16.7% vs. 3.5%; P=0.018), larger vegetations (16.6±8.1mm vs. 12.6±9.9mm; P=0.042) and poorer New York Heart Association status (P=0.006). Overall mortality was lower in the MVRep group than in MVR group (11.3% vs. 29.3%; P=0.018). Event-free survival was better in the MVRep group than in the MVR group in univariate analysis (hazard ratio: 2.72, 95% confidence interval: 1.34-5.52; P=0.004). Survival analysis in the propensity-matched cohort showed that MVRep was safer than MVR (log rank test: P=0.018). Multivariable analysis using the Cox proportional hazard model confirmed this finding (hazard ratio: 3.48, 95% confidence interval: 1.15-10.61; P=0.03). MVRep is feasible in most cases of NMIE and, when technically possible, should be preferred, even in urgent surgery.

Sections du résumé

BACKGROUND BACKGROUND
In native mitral valve infective endocarditis (NMIE), the respective values of mitral valve repair (MVRep) and replacement (MVR) are still debated.
AIM OBJECTIVE
To compare MVRep and MVR in a large prospective matched cohort.
METHODS METHODS
Between 2010 and 2017, all consecutive patients operated on for NMIE in our centre were included prospectively. Clinical and outcome features were compared between the two groups. Primary endpoint was event-free survival, including death, reoperation and relapse. Univariate and multivariable survival analyses and a propensity score analysis were performed.
RESULTS RESULTS
Among 152 patients, 115 (75.7%) underwent MVRep, and 37 (24.3%) MVR. Median follow-up was 28±22months. Surgery was performed during the active phase in 75.0% of patients (25.7% on an urgent basis). Compared with the MVRep group, patients in the MVR group were more frequently intravenous drug abusers (10.8% vs. 0.9%; P=0.016), had a more frequent history of rheumatic fever (13.5% vs. 0%; P=0.001), more aortic abscesses (16.7% vs. 3.5%; P=0.018), larger vegetations (16.6±8.1mm vs. 12.6±9.9mm; P=0.042) and poorer New York Heart Association status (P=0.006). Overall mortality was lower in the MVRep group than in MVR group (11.3% vs. 29.3%; P=0.018). Event-free survival was better in the MVRep group than in the MVR group in univariate analysis (hazard ratio: 2.72, 95% confidence interval: 1.34-5.52; P=0.004). Survival analysis in the propensity-matched cohort showed that MVRep was safer than MVR (log rank test: P=0.018). Multivariable analysis using the Cox proportional hazard model confirmed this finding (hazard ratio: 3.48, 95% confidence interval: 1.15-10.61; P=0.03).
CONCLUSIONS CONCLUSIONS
MVRep is feasible in most cases of NMIE and, when technically possible, should be preferred, even in urgent surgery.

Identifiants

pubmed: 35249849
pii: S1875-2136(22)00035-3
doi: 10.1016/j.acvd.2022.02.002
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

160-168

Informations de copyright

Copyright © 2022 Elsevier Masson SAS. All rights reserved.

Auteurs

Léopold Oliver (L)

Cardiology Department, La Timone Hospital, AP-HM, 13005 Marseille, France.

Marie Leauthier (M)

Cardiology Department, La Timone Hospital, AP-HM, 13005 Marseille, France.

Matthieu Jamme (M)

INSERM UMR 1018/CESP, Université Paris-Saclay, 94807 Villejuif, France.

Florent Arregle (F)

Cardiology Department, La Timone Hospital, AP-HM, 13005 Marseille, France.

Helene Martel (H)

Cardiology Department, La Timone Hospital, AP-HM, 13005 Marseille, France.

Mary Philip (M)

Cardiology Department, La Timone Hospital, AP-HM, 13005 Marseille, France.

Frederique Gouriet (F)

Aix-Marseille University, IRD, AP-HM, MEPHI, IHU-Méditerranée Infection, 13005 Marseille, France.

Jean Paul Casalta (JP)

Aix-Marseille University, IRD, AP-HM, MEPHI, IHU-Méditerranée Infection, 13005 Marseille, France.

Olivier Torras (O)

Cardiology Department, La Timone Hospital, AP-HM, 13005 Marseille, France.

Anne-Claire Casalta (AC)

Cardiology Department, La Timone Hospital, AP-HM, 13005 Marseille, France.

Laurence Camoin-Jau (L)

Aix-Marseille University, IRD, AP-HM, MEPHI, IHU-Méditerranée Infection, 13005 Marseille, France; Department of Haematology, La Timone Hospital, 13005 Marseille, France.

Flora Lavagna (F)

Cardiology Department, La Timone Hospital, AP-HM, 13005 Marseille, France.

Sebastien Renard (S)

Cardiology Department, La Timone Hospital, AP-HM, 13005 Marseille, France.

Pierre Ambrosi (P)

Cardiology Department, La Timone Hospital, AP-HM, 13005 Marseille, France.

Hubert Lepidi (H)

Aix-Marseille University, IRD, AP-HM, MEPHI, IHU-Méditerranée Infection, 13005 Marseille, France.

Frederic Collart (F)

Department of Cardiac Surgery, La Timone Hospital, 13005 Marseille, France.

Sandrine Hubert (S)

Cardiology Department, La Timone Hospital, AP-HM, 13005 Marseille, France.

Michel Drancourt (M)

Aix-Marseille University, IRD, AP-HM, MEPHI, IHU-Méditerranée Infection, 13005 Marseille, France.

Didier Raoult (D)

Aix-Marseille University, IRD, AP-HM, MEPHI, IHU-Méditerranée Infection, 13005 Marseille, France.

Alberto Riberi (A)

Department of Cardiac Surgery, La Timone Hospital, 13005 Marseille, France.

Gilbert Habib (G)

Cardiology Department, La Timone Hospital, AP-HM, 13005 Marseille, France; Aix-Marseille University, IRD, AP-HM, MEPHI, IHU-Méditerranée Infection, 13005 Marseille, France. Electronic address: gilbert.habib3@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH